Evofem Biosciences Secures $10M Loan
Ticker: EVFM · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1618835
Sentiment: neutral
Topics: financing, debt, working-capital
Related Tickers: EVFM
TL;DR
EVFM just got a $10M loan from a big shareholder to keep the lights on.
AI Summary
On July 17, 2024, Evofem Biosciences, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an affiliate of its largest stockholder, which provided a $10 million senior secured term loan. This agreement is intended to provide working capital and support ongoing operations.
Why It Matters
This financing provides Evofem Biosciences with crucial working capital, potentially stabilizing its financial position and enabling continued operations and product development.
Risk Assessment
Risk Level: medium — While the loan provides immediate capital, the company's reliance on stockholder financing and its overall financial health remain key concerns.
Key Numbers
- $10.0M — Senior Secured Term Loan (Provided by an affiliate of the largest stockholder to fund working capital and operations.)
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- $10 million (dollar_amount) — Senior secured term loan amount
- July 17, 2024 (date) — Date of the loan agreement
- Neothetics, Inc. (company) — Former company name
FAQ
What is the purpose of the $10 million loan?
The loan is intended to provide working capital for Evofem Biosciences, Inc. and to support its ongoing operations.
Who provided the $10 million loan to Evofem Biosciences?
The loan was provided by an affiliate of Evofem Biosciences, Inc.'s largest stockholder.
When was the loan agreement entered into?
The Material Definitive Agreement for the loan was entered into on July 17, 2024.
What type of loan is the $10 million facility?
It is a senior secured term loan.
What is the principal business of Evofem Biosciences, Inc.?
Evofem Biosciences, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 1,716 words · 7 min read · ~6 pages · Grade level 12.6 · Accepted 2024-07-23 16:30:11
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $500,000 — ck") for an aggregate purchase price of $500,000.The powers, preferences, rights, qualif
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex10-1.htm (EX-10.1) — 211KB
- ex10-2.htm (EX-10.2) — 292KB
- ex10-3.htm (EX-10.3) — 220KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001493152-24-028818.txt ( ) — 1155KB
- evfm-20240717.xsd (EX-101.SCH) — 3KB
- evfm-20240717_lab.xml (EX-101.LAB) — 33KB
- evfm-20240717_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: July 23, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer